Table 2 Cost-effectiveness results, base case analysis
BAY 81–8973 | rAHF-PFM | Incremental | |
|---|---|---|---|
Drug/Procedure cost | ¥16,329,777 | ¥16,325,648 | ¥4,129 |
Bleeding related costs | ¥486,877 | ¥612,852 | -¥125,974 |
Physician visits | ¥108,348 | ¥108,321 | ¥27 |
Societal cost | ¥5,388 | ¥5,390 | -¥2 |
Total cost | ¥16,930,390 | ¥17,052,210 | -¥121,819 |
QALYs | 13.220 | 13.167 | 0.053 |
Life years | 18.058 | 18.053 | 0.005 |
ICER | BAY 81–8973 is dominant (lower costs and higher QALY gain) | ||